Q1 EPS Estimates for Cabaletta Bio Lifted by HC Wainwright

Cabaletta Bio, Inc. (NASDAQ:CABA) – Investment analysts at HC Wainwright raised their Q1 2026 EPS estimates for shares of Cabaletta Bio in a research report issued to clients and investors on Wednesday, April 1st. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.39) per share for the quarter, up from their prior forecast of ($0.47). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.51) EPS, Q4 2027 earnings at ($0.37) EPS, FY2027 earnings at ($1.48) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.64) EPS.

CABA has been the topic of a number of other research reports. Wall Street Zen upgraded Cabaletta Bio from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Guggenheim raised their price objective on Cabaletta Bio from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a report on Wednesday, January 21st. Finally, Morgan Stanley decreased their target price on Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 24th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $17.00.

Cabaletta Bio Stock Performance

Shares of Cabaletta Bio stock opened at $2.96 on Friday. The company has a 50-day moving average of $2.93 and a two-hundred day moving average of $2.59. Cabaletta Bio has a 12-month low of $0.99 and a 12-month high of $3.78. The stock has a market cap of $329.51 million, a PE ratio of -1.30 and a beta of 3.30.

Cabaletta Bio (NASDAQ:CABA) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.05.

Insider Buying and Selling

In related news, CEO Steven Nichtberger purchased 45,000 shares of the company’s stock in a transaction on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the completion of the transaction, the chief executive officer owned 1,031,483 shares of the company’s stock, valued at approximately $2,310,521.92. This represents a 4.56% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark Simon purchased 11,061 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was bought at an average cost of $2.28 per share, with a total value of $25,219.08. Following the completion of the acquisition, the director owned 147,205 shares of the company’s stock, valued at approximately $335,627.40. The trade was a 8.12% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 127,668 shares of company stock worth $286,211 in the last quarter. Corporate insiders own 11.25% of the company’s stock.

Institutional Trading of Cabaletta Bio

A number of large investors have recently made changes to their positions in the stock. Invesco Ltd. increased its position in Cabaletta Bio by 357.1% during the 1st quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock worth $85,000 after purchasing an additional 48,181 shares in the last quarter. Comerica Bank lifted its holdings in Cabaletta Bio by 2,292.1% in the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after purchasing an additional 39,860 shares in the last quarter. AQR Capital Management LLC purchased a new position in Cabaletta Bio in the 1st quarter valued at about $102,000. XTX Topco Ltd acquired a new stake in shares of Cabaletta Bio during the 2nd quarter worth about $148,000. Finally, Marshall Wace LLP boosted its stake in shares of Cabaletta Bio by 470.7% during the 2nd quarter. Marshall Wace LLP now owns 190,957 shares of the company’s stock worth $290,000 after purchasing an additional 157,497 shares during the last quarter.

More Cabaletta Bio News

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised multiple quarterly and annual EPS forecasts (example: FY2026 to ($1.51) from ($1.89); FY2027 to ($1.48) from ($1.97); FY2028 to ($1.41) from ($1.86); FY2029 to ($0.64) from ($0.92)), signaling improving expectations for Cabaletta’s financial trajectory. MarketBeat: CABA analyst updates
• Positive Sentiment: HC Wainwright also updated quarterly 2026 estimates (Q1–Q4 2026 moved roughly from ~$0.47 loss per share to ~$0.36–$0.40 loss per share), which could reduce near‑term downside risk if company performance follows these assumptions. MarketBeat: CABA analyst updates
• Neutral Sentiment: Despite upgrades, consensus full‑year estimates remain negative (MarketBeat consensus listed at about ($2.34) per share), and meaningful profitability is projected only in the long term (FY2030). The stock remains a speculative, binary biotech investment dependent on clinical and commercial execution. MarketBeat: CABA consensus data

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.